Utah Medical Products Inc - UTMD STOCK NEWS

On April 22, 2021, Utah Medical Products reported its financial results for Q1 2021, highlighting a solid performance despite ongoing pandemic challenges. Key metrics showed a 1% increase in revenues and a 2% rise in gross profit compared to Q1 2020. Operating income also grew by 1%, while net income fell by 4% due to lower non-operating income. Despite challenges in device sales, particularly the Filshie device, the company anticipates a 25% revenue increase for Q2 2021 vs. Q2 2020. Cash and investments reached $56 million, reflecting a healthy balance sheet with no debt.

Utah Medical Products, Inc. (Nasdaq: UTMD) announced the termination of its Shareholder Rights Agreement by unanimous consent of the Board of Directors. Originally approved in 1994 and extended multiple times, the decision reflects evolving corporate governance standards and shareholder feedback. The company focuses on developing specialty medical devices for women and infants, recognized worldwide for their quality. This strategic move aims to align with changing investor expectations and modern governance practices.

Utah Medical Products (NASDAQ:UTMD) has declared a quarterly cash dividend of $.285 per share, to be paid on April 2, 2021, to shareholders on record by March 17, 2021. This dividend reflects a 2% increase compared to the previous year’s quarter. The company remains focused on providing medical devices in the women's health sector, recognized for their quality by clinicians in over 100 countries.

Utah Medical Products (Nasdaq: UTMD) reported its 4Q 2020 financial results showing recovery from pandemic impacts, achieving its best revenue quarter of the year. 4Q 2020 revenues were nearly 2% higher than pre-pandemic 4Q 2019. However, total 2020 revenues were 10% lower than 2019. Direct sales to end users were down 14% for the year, indicative of ongoing challenges. Foreign exchange rates positively impacted 4Q revenues by 1.1%. Operating income margins dropped to 35.6% in 4Q 2020 from 39.5% in 4Q 2019, largely due to increased expenses related to investment and pandemic responses.

Utah Medical Products, Inc. (NASDAQ:UTMD) has announced a quarterly cash dividend of $0.285 per share, payable on January 5, 2021, to shareholders on record by the close of business on December 15, 2020. This represents a 2% increase from the previous quarterly dividend. The company specializes in developing, manufacturing, and marketing specialty medical devices, focusing on healthcare for women and their babies, and is recognized globally for its commitment to optimal patient outcomes.

Utah Medical Products (Nasdaq: UTMD) reported a significant decline in revenues for 3Q and 9M 2020, primarily due to COVID-19 restrictions affecting nonessential medical procedures. U.S. domestic sales fell by 8% in 3Q 2020 from the previous year, while OUS sales dropped by 28%. Despite the downturn, there was a recovery in U.S. sales from the previous quarter. Management anticipates a continued positive trend in 4Q 2020, assuming no further healthcare restrictions. The company maintained a strong balance sheet with $46.3 million in cash and no debt.

Utah Medical Products (NASDAQ:UTMD) has declared a quarterly cash dividend of $0.28 per share, to be paid on October 5, 2020, to shareholders on record as of September 15, 2020. This marks a 2% increase over the previous year's dividend for the same quarter. The company specializes in healthcare solutions for women and infants and is recognized for its specialty medical devices used globally. This dividend decision reflects the company's ongoing financial commitment to its shareholders.

Utah Medical Products, Inc. (NASDAQ:UTMD) announced a quarterly cash dividend of $0.28 per share, set to be paid on October 5, 2020. This marks a 2% increase from the previous year's dividend issued in the same quarter. Shareholders on record as of September 15, 2020 will be eligible for this payment. The company focuses on developing and marketing specialty medical devices aimed at enhancing healthcare outcomes for women and infants worldwide.

On July 28, 2020, Utah Medical Products reported significant declines in financial performance for Q2 and H1 2020, attributed mainly to the COVID-19 pandemic affecting elective medical procedures. Q2 sales dropped by 26%, with gross profit declining 34%. Operating income fell by 56%, resulting in a net income decrease of 63%. Despite these challenges, the company maintains strong financial stability, with cash reserves of $42.4 million and continued profitability during the shutdown. Management anticipates a recovery driven by government policy responses.